PO69 | INCIDENTAL CANCER DETECTED DURING EMERGENCY DIAGNOSTIC WORK-UP FOR ACUTE PULMONARY EMBOLISM: A RETROSPECTIVE COHORT STUDY
L. Mocerino1, A. Casoria2, S. Mangiacapra2, M. Amitrano2, V. Bassi3, A. Tufano1 | 1Department of Clinical Medicine and Surgery. Federico II University of Naples, Italy; 2Internal Medicine Unit, Moscati Hospital, Avellino, Italy; 3U.O.C. di Medicina Generale e Lungodegenza, San Giovanni Bosco Hospital, ASL; Na1 Centro, Naples, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background. Pulmonary embolism (PE) may represent the first clinical manifestation of an occult malignancy. The prevalence of incidentally detected cancer during emergency department (ED) diagnostic work-up for acute PE remains incompletely characterized, particularly in the presence of provoking factors.
Objectives. To estimate the prevalence of incidental cancer detected during ED investigations for acute PE, to describe the cancer types, and to distinguish between provoked and unprovoked PE cases.
Methods. We conducted a retrospective observational study including 93 consecutive patients admitted with acute PE. Incidental cancer was defined as a previously unknown malignancy detected during diagnostic investigations performed for PE in the ED. PE was classified as provoked or unprovoked based on the presence of identifiable transient or persistent risk factors.
Results. Incidental cancer was detected in 21 of 93 patients (22.6%). Lung cancer was the most frequent malignancy (33.3%), followed by colorectal cancer (23.8%). Notably, 19 of 21 incidental cancers (90.5%) occurred in patients with unprovoked PE, whereas only 2 cases (9.5%) were observed among patients with provoked PE. The prevalence of incidental cancer was 32.8% in unprovoked PE compared with 5.7% in provoked PE. Median age was 75 years (IQR 65–81), and 53.8% of patients were female.
Conclusions. In this cohort, nearly one quarter of patients presenting with acute PE had an incidentally detected malignancy during PE work-up, with the vast majority occurring in unprovoked PE setting. These findings reinforce the role of unprovoked PE as a potential early marker of occult cancer and support careful evaluation of incidental imaging findings in this population.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO38 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
